Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for a doubling in hormone concentration for all women and according to subject characteristicsa

From: Premenopausal serum androgens and breast cancer risk: a nested case-control study

Characteristic Hormone
(number of cases) Testosterone Free Testosterone Androstenedione DHEAS SHBG
All women (n = 354)      
   OR (95% CI) 1.6 (1.2, 2.3) 1.3 (1.1, 1.5) 1.3 (1.0, 1.7) 1.1 (0.9, 1.4) 0.9 (0.8, 1.1)
   P-value 0.01 0.003 0.07 0.31 0.47
Tumor type      
   Invasive (n = 274)      
OR (95% CI) 1.5 (1.1, 2.2) 1.2 (1.0, 1.4) 1.3 (0.9, 1.8) 1.1 (0.8, 1.4) 1.0 (0.8, 1.2)
P-value 0.03 0.02 0.11 0.60 0.84
   In situ (n = 80)      
OR (95% CI) 2.3 (0.9, 5.9) 1.4 (1.0, 2.1) 2.0 (0.9, 4.5) 1.6 (0.9, 2.8) 0.8 (0.5, 1.3)
P-value 0.09 0.07 0.10 0.14 0.37
Estrogen receptor statusb      
   Positive (n = 104)      
OR (95% CI) 2.4 (1.2, 4.6) 1.6 (1.2, 2.2) 2.2 (1.3, 3.8) 1.2 (0.8, 1.8) 0.9 (0.6, 1.3)
P-value 0.01 0.003 0.01 0.42 0.56
   Negative (n = 60)      
OR (95% CI) 1.7 (0.7, 4.3) 1.2 (0.9, 1.8) 0.7 (0.3, 1.6) 1.4 (0.7, 2.6) 0.8 (0.5, 1.4)
P-value 0.25 0.26 0.37 0.34 0.41
Age at enrollmentc      
   < 40 yrs (n = 77)      
OR (95% CI) 1.7 (0.7, 4.2) 1.3 (0.9, 2.0) 1.3 (0.6, 2.7) 0.9 (0.5, 1.5) 0.7 (0.4, 1.2)
P-value 0.27 0.19 0.45 0.61 0.17
   40- to yrs (n = 117)      
OR (95% CI) 1.4 (0.7, 2.6) 1.1 (0.8, 1.4) 1.1 (0.7, 1.8) 1.1 (0.8, 1.6) 1.2 (0.8, 1.8)
P-value 0.33 0.50 0.72 0.53 0.36
   ≥45 yrs (n = 160)      
OR (95% CI) 1.9 (1.2, 3.2) 1.4 (1.1, 1.7) 1.5 (1.0, 2.3) 1.2 (0.9, 1.7) 0.9 (0.7, 1.2)
P-value 0.01 0.004 0.08 0.21 0.57
Menopausal status at diagnosisd, e      
   Pre (n = 152)      
OR (95% CI) 1.4 (0.8, 2.3) 1.1 (0.9, 1.4) 1.0 (0.7, 1.5) 1.1 (0.8, 2.5) 1.0 (0.8, 1.4)
P-value 0.23 0.36 0.98 0.56 0.80
   Post (n = 161)      
OR (95% CI) 1.7 (1.1, 2.6) 1.3 (1.1, 1.6) 1.3 (0.9, 1.9) 1.2 (0.8, 1.6) 0.9 (0.7, 1.1)
P-value 0.02 0.006 0.18 0.39 0.26
BMId      
   < 25 kg/m2 (n = 239)      
OR (95% CI) 1.8 (1.2, 2.6) 1.3 (1.1, 1.5) 1.2 (0.9, 1.6) 1.3 (1.0, 1.6) 0.9 (0.7, 1.1)
P-value 0.003 0.003 0.30 0.08 0.41
25 to 29.9 kg/m2 (n = 74)      
OR (95% CI) 2.4 (1.1, 5.0) 1.5 (1.1, 2.1) 1.9 (1.0, 3.5) 1.3 (0.8, 2.1) 1.1 (0.8, 1.7)
P-value 0.02 0.01 0.05 0.29 0.58
≥30 kg/m2 (n = 108)      
OR (95% CI) 1.5 (0.8, 2.7) 1.2 (0.9, 1.6) 1.6 (1.0, 2.5) 1.0 (0.7, 1.5) 1.1 (0.8, 1.5)
P-value 0.20 0.11 0.08 0.95 0.64
Lag time between blood donation and diagnosisf      
   < 7 yrs (n = 154)      
OR (95% CI) 2.0 (1.1, 3.5) 1.3 (1.0, 1.7) 1.3 (0.9, 2.1) 1.4 (1.0, 1.9) 1.0 (0.8, 1.5)
P-value 0.02 0.04 0.20 0.06 0.78
   ≥7 yrs (n = 200)      
OR (95% CI) 1.5 (1.0, 2.3) 1.3 (1.0, 1.5) 1.3 (0.9, 1.9) 1.0 (0.7, 1.3) 0.8 (0.6, 1.1)
P-value 0.07 0.02 0.17 0.80 0.22
5 to7 cycles in 6 months prior to enrollment and regular cyclesd (n = 253)      
OR (95% CI) 1.6 (1.1, 2.3) 1.2 (1.1, 1.5) 1.3 (1.0, 1.8) 1.1 (0.9, 1.5) 0.9 (0.8, 1.2)
P-value 0.02 0.01 0.07 0.29 0.59
  1. aAdjusted for age at menarche (< 12, 12, 13, > 13, missing), family history of breast cancer (no, one affected first-degree relative > 45 yrs old, one affected first degree relative < 45 yrs old or more than one affected first-degree relative), parity/age at first birth (≤20 years at first full-term pregnancy, 21 to 25 years at first full-term pregnancy, 26 to 30 years at first full-term pregnancy, > 30 years at first full-term pregnancy, nulliparous, missing), history of breast biopsy, and body mass index (< 20, 20-22.5, 22.6-24.9, 25-29.9, 30+, missing). b0.05 <Pinteraction < 0.15 for androstenedione. c0.05 <Pinteraction < 0.15 for free testosterone. dUsing unconditional logistic regression, adjusting for matching factors in addition to factors listed in a. e 0.05 <Pinteraction < 0.15 for free testosterone. f0.05 <Pinteraction < 0.15 for SHBG. DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.